75815-22-4

Basic information

• Product Name: 2-bromo-2'-chloropropiophenone
• Synonyms: 2-bromo-2'-chloropropiophenone;2-bromo-1-(2-chlorophenyl)propan-1-one;2-Bromo-1-(2-chlorophenyl)-1-propanone;2'-Chloro-α-bromopropiophenone
• CAS NO: 75815-22-4
• Molecular Formula: C₉H₈BrClO
• Molecular Weight: 247.51622
• EINECS: 278-320-7
• Mol File: 75815-22-4.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 140-143 °C(Press: 15 Torr)
• Appearance: /
• Density: 1.5233 g/cm3(Temp: 22 °C)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-bromo-2'-chloropropiophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-2'-chloropropiophenone(75815-22-4)
• EPA Substance Registry System: 2-bromo-2'-chloropropiophenone(75815-22-4)

Safety Data

• Hazardous Substances Data: 75815-22-4(Hazardous Substances Data)

Usage

Uses

2-Bromo-2''-chloropropiophenone is used as a reagent in the synthesis of 2-(tert-Butylamino)-3’,4’-dichloropropiophenone Hydrochloride (B690685); an impurity of Bupropion (B689625, HCl) which has inhibitory effects on monoamine uptake and antagonizes the effects of human α3β4*, α4β2, α4β4, and α1* nicotinic acetylcholine receptors (nAChRs).

Upstream product

• 873-32-5 2-Chlorobenzonitrile 
• 609-65-4 o-chlorobenzoyl chloride 
• 89-98-5 2-chloro-benzaldehyde 
• 22869-35-8 2-chloro-α-ethylbenzyl alcohol 
• 6323-18-8 2-chloropropiophenone 

Downstream Products

• 90919-30-5 1-o-Chlor-phenyl-1-methoxy-aceton 
• 90869-66-2 1-(2-chlorophenyl)-2-(methylamino)propan-1-one hydrochloride 

Relevant articles and documents

Structure-based design of potent human dihydroorotate dehydrogenase inhibitors as anticancer agents

It has been proven that inhibiting human dihydroorotate dehydrogenase (hDHODH) restricts the growth of rapidly proliferating cells, thus hDHODH can be developed as a promising target for the treatment of immunological disease and cancer. Here, a succession of substituted hydrazino-thiazole derivatives were designed, synthesized, and biologically evaluated through structure-based optimization, of which compound 22 was the most potent inhibitor of hDHODH with an IC50 value of 1.8 nM. Furthermore, 22 exhibited much better antiproliferative activity than brequinar, both in HCT-116 and BxPC-3 cancer cell lines. Flow cytometry analysis revealed that 22 induced S phase cell cycle arrest and promoted induction of apoptosis. All results established a proof that blocking the pyrimidine de novo synthesis pathway by inhibiting the rate-limiting enzyme hDHODH is an attractive therapy for cancer.

Pyrrole derivatives and medicinal composition

The invention relates to a pharmaceutical composition comprising a pyrrole derivative of the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate of either of them, as an active ingredient. STR1 (wherein R1 represents hydrogen or alkoxycar91 bonylamino, R2 represents alkyl, aryl which may be substituted, aromatic heterocyclyl which may be substituted, unsubstituted amino, monoalkylamino, dialkylamino, or cyclic amino which may be substituted; R3 represents cyano or carbamoyl; R4 represents hydrogen or alkyl; E represents alkylene; q is equal to 0 or 1, A represents methyl, aryl which may be substituted, or aromatic heterocyclyl which may be substituted). The pharmaceutical composition of the invention is effective for the treatment of pollakiuria or urinary incontinence.